This page shows the latest AndroGel news and features for those working in and with pharma, biotech and healthcare.
Among other products, HIV therapy Kaletra (lopinavir/ ritonavir) rose 1.1 per cent to $278m, while revenue from testosterone replacement therapy AndroGel fell 6.5 per cent to $258m.
involving testosterone replacement therapy product AndroGel should be allowed to go forward.
Top of the list in the speciality division is testosterone replacement therapy AndroGel – 31 per cent to $1.15bn in 2012 – with support from Creon (pancrelipase) for pancreatic insufficiency and hypothyroidism
arthritis treatment Humira (adalimumab), which was up 16.5 per cent $2.33bn, and testosterone gel Androgel, which grew 24.7 per cent to $276m.
Solvay's product portfolio includes the testosterone gel AndroGel, the progesterone capsule Prometrium, and the pancreatic enzyme replacement therapy Creon (pancreatin).
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
This is not the first such case for Teva, as the FTC also filed suit last September for an alleged pay for delay relating to AndroGel.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...